Fundamental Analysis (Long term)

18 Jul 2025 09:09

DEEP INDUSTRIES Management says Expecting Aditional Revenue Of ₹350-400 Cr Post Capex - NDTV PROFIT

Has Acquired More Than 3 Companies From Insolvency

To Improve EBITDA Margins To 45% With The Acquisition Of Dolphin Offshore & Kandla Energy

Plan To Raise Equities Via QIP

Expect To Grow Above 30% For The Next Two Financial Years

Expecting Year-On-Year Growth Of 30%

Capex To Be Funded By Mix Of Internal Accruals, Debt

Comfortable On Taking Debt Because Of Low Leverage

Looking Forward For Value Recognition By Market

Current Cost Of Debt Remains At 8.2-8.5%

Fundamental Analysis (Long term)

17 Jul 2025 17:40

Peer Comparison:

Transformer Companies with its Capacities, Order Book, Mcap and its valuation.

Fundamental Analysis (Long term)

17 Jul 2025 12:03

🔸Divi’s is focusing on GLP-1, GIP, and GLP-2 therapies through advanced peptide synthesis for innovators. It avoids the generic space, with several custom projects in the pipeline and expected revenues from late 2026.

Fundamental Analysis (Long term)

17 Jul 2025 12:03

🔸Sai Life Sciences inaugurated a peptide R&D center with advanced automated synthesis capabilities and USFDA GMP certification.

Fundamental Analysis (Long term)

17 Jul 2025 12:02

🔸Aarti Pharmalabs Ltd is actively expanding into peptide and biotech product development, moving beyond its core small molecule focus

Fundamental Analysis (Long term)

17 Jul 2025 12:02

🔸Dr. Reddy’s is developing generic semaglutide (GLP-1) and plans to launch it in 2026 across markets where patents allow.

Fundamental Analysis (Long term)

17 Jul 2025 12:02

🔸Granules India acquired Swiss CDMO Senn Chemicals AG, boosting peptide synthesis and enabling international scale-up.

Fundamental Analysis (Long term)

17 Jul 2025 12:01

🔸Wockhardt is developing GLP-1 analogs like semaglutide to tap into the rising global demand for advanced diabetes treatments, strengthening its position in the $3 billion diabetes market.

Fundamental Analysis (Long term)

17 Jul 2025 12:01

🔷Competitive Landscape: Key Players and Pipeline Developments:

🔸Market Leaders and Innovators
🔹Novo Nordisk dominates the current Indian GLP-1 market, primarily through oral semaglutide (Rybelsus), which holds approximately 69% market share as of recent reports.
🔹Eli Lilly launched tirzepatide (Mounjaro) in India, expanding therapeutic options with a dual GIP/GLP-1 receptor agonist.
🔹Cipla, Dr. Reddy’s Laboratories, Lupin, and Sun Pharma are aggressively advancing generic or novel GLP-1 therapies, with regulatory filings and R&D pipelines targeting both domestic and international markets.
🔹Glenmark has already introduced a generic liraglutide in 2024, signaling the early start of generic competition.
🔹Piramal Pharma operates USFDA-approved peptide API manufacturing at its Turbhe site, catering to growing generic peptide demand.
🔹Biocon Ltd has received approval from the USFDA for Kirsty as the first and only interchangeable biosimilar to NovoLog (Insulin Aspart).

Fundamental Analysis (Long term)

17 Jul 2025 12:00

🔸Reports suggest that multiple generics will be approved by the Drug Controller General of India (DCGI) by late 2025, potentially ushering in price competition that could reduce therapy costs by 50-70%, according to JM Financial.

🔸Supporting the supply chain, firms like Biocoin, Divi’s Laboratories are providing key synthetic components, while Shaily Engineering and OneSource Specialty Pharma handle pen manufacturing and fill-finish processes.

Fundamental Analysis (Long term)

17 Jul 2025 11:39

💊 Glucagon-like Peptide-1 (GLP-1) Patent Expiry in 2026 Opens the Door for Many

💊Which Indian companies are racing to capture this $150 billion opportunity?

Fundamental Analysis (Long term)

17 Jul 2025 06:42

Unlikely to see upgrades on a broad basis, markets taking a breather. Positive on broader consumer discretionary: hospitals, hotels & capital markets

It’s a stock-picking market at this point, says Trideep Bhattacharya of #EdelweissAMC to CNBC-TV18

Fundamental Analysis (Long term)

16 Jul 2025 13:31

Quarterly Result update and Live stock news
@Stockupdate9

Fundamental Analysis (Long term)

16 Jul 2025 06:33

Don't like 3–4% growth trajectory, although broadly like the market. India has a strong case with favourable readings on inflation, interest rates & more

Expect financials to see recovery in growth rate, says Samir Arora of #HeliosCapital to CNBC-TV18

Fundamental Analysis (Long term)

15 Jul 2025 06:15

Tata Tech shares higher in opening trade, up nearly 3%, as mgmt provides with positive outlook for #Q2 and #FY26

#TataTech says:

▶️Very confident we will not decline in FY26

▶️Confident that Q2 will be better than Q1 & a strong H2

▶️Confident of margin trending towards 18% this year & our north star is 20%

Fundamental Analysis (Long term)

18 Jul 2025 09:07

CEAT Management says Q1 Was Heavy On Ad Spends Mainly Because Of IPL - CNBCTV18

Expect Q2 To Be Better Than Q1 On Order Visibility

See Margin Improving In Q2 On Lower Raw Material Costs

Have Gained Market Share In Replacement Segment (Both PV & Bike)

Do Not Have Major Order Visibility On Export Front For Q3 & Q4

Fundamental Analysis (Long term)

17 Jul 2025 12:03

Credit: Raghav Wadhwa

Fundamental Analysis (Long term)

17 Jul 2025 12:03

🔸Aurobindo Pharma has developed the entire GLP-1 product range, including Liraglutide and Semaglutide, and plans to file from its new Vizag plant using a dedicated cartridge line.

Fundamental Analysis (Long term)

17 Jul 2025 12:03

🔸Neuland Laboratories approved ₹342 crore capex to increase peptide synthesizer capacity sixfold by FY27.

Fundamental Analysis (Long term)

17 Jul 2025 12:02

🔸Blue Jet Healthcare invested ₹40 crore into peptide and GLP-1 intermediates R&D in Hyderabad.

Fundamental Analysis (Long term)

17 Jul 2025 12:02

🔸Gland Pharma's entry into the GLP-1 segment began with the launch of liraglutide, and with two GLP-1 contracts secured, they are scaling cartridge capacity from 40 million to 140 million units by CY26.

Fundamental Analysis (Long term)

17 Jul 2025 12:01

🔸OneSource Specialty Pharma’s USFDA-compliant facility will support the commercial launch of key GLP-1 products for its partners by late FY26.

Fundamental Analysis (Long term)

17 Jul 2025 12:01

🔷Government Support:
🔸The Production-Linked Incentive scheme encourages local manufacturing of GLP-1 drugs post-2026 patent expiry. Major pharma firms are applying, signaling strong government-industry collaboration to reduce import reliance and improve margins.
🔷Recent R&D and Capacity Expansion Highlights: India’s pharma sector is witnessing substantial investment in peptide therapeutics, critical for GLP-1 drug development:
🔸Biocon Ltd has received approval from the USFDA for Kirsty as the first and only interchangeable biosimilar to NovoLog (Insulin Aspart).

Fundamental Analysis (Long term)

17 Jul 2025 12:00

🔷Why GLP-1 Drugs Are Gaining Spotlight in India

🔸India faces a growing health crisis with rising obesity and type 2 diabetes, projected to impact over 11% of adults by 2035. GLP-1 receptor agonists are gaining attention for offering dual benefits: effective blood sugar control and significant weight loss.

🔸However, most of these drugs are expensive imports from the US, with monthly costs often exceeding ₹20,000 (e.g., Wegovy and Ozempic), making them unaffordable for many. This has created a strong push for domestic manufacturing, especially with patent expiries and government support likely through PLI schemes. As a result, the Indian GLP-1 market is expected to grow rapidly at a 34.3% CAGR through 2030.

Fundamental Analysis (Long term)

17 Jul 2025 11:40

🔸GLP-1 drugs mimic the hormone glucagon-like peptide-1, helping regulate blood sugar by boosting insulin, reducing glucagon, slowing digestion, and increasing satiety. They are primarily used to treat type 2 diabetes, with popular options including semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda).

🔸These drugs have recently gained attention for their weight loss benefits, showing significant results in both diabetic and non-diabetic patients. Their ability to aid weight management and improve heart health has made them a breakthrough in diabetes and obesity care.

🔷Patent Expiry and Market Dynamics: The Door Opens for Indian Generics:
🔸A pivotal event shaping the GLP-1 market in India is the scheduled expiration of Novo Nordisk’s patent for semaglutide (marketed as Wegovy and Ozempic) in 2026. This patent cliff creates an opportunity for Indian pharmaceutical manufacturers to launch generic versions, which is likely to drive down prices and expand patient access.

Fundamental Analysis (Long term)

17 Jul 2025 11:33

KP Energy – FY26: Wind Infra Compounder in the Making

- While large infra gets headlines, the real compounding is happening where few look, in execution, grid, and annuity.
- Here’s why KP Energy might be India’s next great infra enabler

1️⃣ A Wind Infra Specialist With Operating Muscle
▪️FY25 Revenue: ₹958 Cr (+97%)
▪️PAT: ₹115 Cr | EBITDA Margin: 19%
▪️ROE > 35% | EPS: ₹17.3 (vs ₹8.8)
Not just growth profitable, cash-generating growth.

2️⃣ A ₹2,800 Cr Order Book Isn’t Just Big - It’s Smart
▪️2.26 GW in hand (across clients + states)
▪️500 MW of new orders expected by Sep ‘25
▪️3.5 GW bid pipeline under evaluation
Execution backlog till FY26 is locked and loaded.

3️⃣ Execution Is a Moat, Not a Buzzword
▪️In-house SCADA, cranes, LIDAR, met-masts
▪️CTU/STU grid connectivity pre-secured
▪️Early project completion track record
Infra operating leverage → faster delivery, lower cost.

4️⃣ EPC Is the Cash Engine
▪️97% of revenue from BoP EPC
▪️₹196 Cr EBITDA with milestone billing
▪️Negative working capital cycle
Clean model + strong margins = core compounding engine.

5️⃣ IPP Portfolio: Building the Annuity Layer
▪️48.5 MW now → 100 MW by FY27
▪️₹2.43/unit tariff for new project
▪️IRR intact due to infra reuse & captive ops
Every MW added creates recurring, de-risked income.

6️⃣ O&M Is a Small Flywheel Now - But Watch It Turn
▪️₹4.5 Cr in FY25 → ₹6.5 Cr FY26
▪️546 MW under mgmt; assets aging into paid service
▪️Low cost, high IRR vertical
Infra lifecycle monetisation is the hidden compounding layer.

7️⃣ Offshore Wind: 2 GW of Silent Optionality
▪️Govt tenders in Gujarat & TN underway
▪️70 GW national potential
▪️KP + KPI Green consortium ready to bid
Few midcaps have offshore positioning. KP already does.

8️⃣ Clients Are Blue-Chip. Orders Are Strategic.
▪️Aditya Birla, NTPC, GUVNL, recurring business
▪️1.2 GW internal EPC order from KPI Green (to Oct ’26)
▪️Even delayed projects (NTPC/INGEL) now progressing
The client list says it all, reputation = repeatability.

9️⃣ FY26 Guidance Is Bold and Backed By Execution
▪️60-70% YoY revenue growth guided
▪️₹2,800 Cr backlog, 3.5 GW pipeline
▪️Margins to remain ~19%
Unlike others, KP’s guidance is grounded in booked orders, not hope.

🔟 What’s the Real Opportunity Here ?
- It’s not just about EPC or wind or orders.
- It’s about:
✓ A scalable, execution-focused infra platform
✓ A founder-led group with annuity layering
✓ Clean balance sheet + optionality in offshore
- This is not a story of wind. It’s a story of infra done right.

🧭Investors Compass Take
– KP Energy = Infra Optionality + Execution Moat + Earnings Durability
- In a sector full of noise, KP has quietly built:
▪️Visibility
▪️Profitability
▪️Repeatability
▪️Optionality
➡️ The rerating will follow the results.

Fundamental Analysis (Long term)

17 Jul 2025 05:43

June General Insurance Data – Nuvama

🔸 BAGIC: GDPI jumped +17.1% YoY, led by: ▪️ Fire 🔥 +27.6%
▪️ Motor TP 🚗 +62.4%
▪️ Retail Health +13% (beat industry)
▪️ Group GDPI ▼5.6%
▪️ Motor OD +14.6%
📌 Rating: HOLD | TP: ₹2,000

🔸 ICICI GI: Total GDPI ▼10.4% YoY
▪️ Motor ▼2.1% (OD +0.8%, TP ▼5%)
▪️ Retail Health +31.2% 🚀
▪️ Group Health ▼11.9%
📌 Rating: BUY | TP: ₹2,340

🔸 Star Health (STARHEAL):
▪️ Retail Health GDPI +8.7% YoY
▪️ Overall Health GDPI +3.2%
▪️ Group Health ▼47.3%
📌 Rating: BUY | TP: ₹500

🔸 Go Digit:
▪️ Motor GDPI +6.8% (TP +9.7%, OD +2.1%)
▪️ Health GDPI +6.7% (Group +6%)

🔸 Niva Bupa:
▪️ Total Health GDPI +16.3% YoY
(Retail +10.7%, Group +30.5%)

Fundamental Analysis (Long term)

16 Jul 2025 11:14

Oberoi Realty - Future Outlook

Pre‐sales to clock 46% CAGR over FY25–27E, rising from ~₹53 b in FY25 to ~₹112 b by FY27

Annuity portfolio
Rental income from office & retail assets to grow at ~29% CAGR over FY25–27E, reaching ~₹13 b by FY27

Collections & Cash flows:
- Residential collections to rise at 30% CAGR to ₹90 b by FY27
- Operating cash flow to clock 38% CAGR to ₹73 b by FY27

Lease rentals from commercial portfolio to post ~27% CAGR to ~₹7 b by FY27

Key growth triggers

Robust launch pipeline: new towers in Borivali, Goregaon, Forestville; projects in Gurugram, Adarsh Nagar, Worli, Tardeo.
Alibaug land in design phase

Commercial occupancy ramp‑up: Commerz III at 81% in 4Q FY25, full leasing of all office assets by FY26E

Net debt/equity at 0.01× in FY25

src : MOFSL

Fundamental Analysis (Long term)

15 Jul 2025 10:52

Landmark Cars :

Q1 FY26 revenue rose 21.56% YoY to ₹1,415 crore, with vehicle sales growing 24.6% and after-sales services up 8.3%.

The company expanded its network with new Kia workshops in Hyderabad and began Mercedes-Benz operations in Patna.

It plans to open a Mahindra outlet in Kolkata and Kia mini outlets in Hyderabad and Kolkata.

MG Select operations will start in Ahmedabad and Kolkata, focusing on high-demand EV models like Cyberster and M9.

Fundamental Analysis (Long term)

15 Jul 2025 06:11

Tata Tech Ceo Says Confident In The JLR Story, And Our Ability To Contribute

Have Been Excited With The Performance That JLR Has Made

Very Confident We Will Not Decline In FY26

Confident That Q2 Will Be Better Than Q1 & A Strong H2